• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种假设的全变体新冠疫苗的局限性:一项模拟研究

The Limitations of a Hypothetical All-Variant COVID-19 Vaccine: A Simulation Study.

作者信息

Kosinski Robert J

机构信息

Independent Researcher, 303 Tamassee Drive, Clemson, SC 29631, USA.

出版信息

Vaccines (Basel). 2024 May 13;12(5):532. doi: 10.3390/vaccines12050532.

DOI:10.3390/vaccines12050532
PMID:38793783
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11126006/
Abstract

This paper simulates a hypothetical pan-coronavirus vaccine that confers immediate sterilizing immunity against all SARS-CoV-2 variants. Simulations used a SEIIS (susceptible, exposed, infective, immune, susceptible) spreadsheet model that ran two parallel subpopulations: one that accepted vaccination and another that refused it. The two subpopulations could transmit infections to one another. Using data from the United States (US), the simulated vaccine was tested against limiting factors such as vaccine hesitancy, slow vaccination distribution, and the development of high-transmission variants. The vaccine was often successful at reducing cases, but high-transmission variants and discontinuation of non-pharmaceutical interventions (NPIs) such as masking greatly elevated cases. A puzzling outcome was that if NPIs were discontinued and high-transmission variants became common, the model predicted consistently higher rates of disease than are actually observed in the US in 2024. However, if cumulative exposure to virus antigens increased the duration of immunity or decreased the infectivity of the virus, the model predictions were brought back into a more realistic range. The major finding was that even when a COVID-19 vaccine always produces sterilizing immunity against every SARS-CoV-2 variant, its ability to control the epidemic can be compromised by multiple common conditions.

摘要

本文模拟了一种假设的泛冠状病毒疫苗,该疫苗能对所有新冠病毒变异株立即产生绝育免疫。模拟使用了一个SEIIS(易感、暴露、感染、免疫、易感)电子表格模型,该模型运行两个平行的亚群体:一个接受疫苗接种,另一个拒绝接种。这两个亚群体可以相互传播感染。利用来自美国的数据,对模拟疫苗进行了针对疫苗犹豫、疫苗接种分布缓慢以及高传播变异株出现等限制因素的测试。该疫苗在减少病例方面通常很成功,但高传播变异株以及诸如戴口罩等非药物干预措施(NPIs)的停止实施极大地增加了病例数。一个令人困惑的结果是,如果停止实施非药物干预措施且高传播变异株变得普遍,该模型预测的疾病发生率始终高于2024年美国实际观察到的发生率。然而,如果累积接触病毒抗原增加了免疫持续时间或降低了病毒的传染性,模型预测结果就会回到更现实的范围。主要发现是,即使一种新冠疫苗始终能对每一种新冠病毒变异株产生绝育免疫,其控制疫情的能力仍可能受到多种常见情况的影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b874/11126006/c8f72f6fe9ea/vaccines-12-00532-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b874/11126006/c8f72f6fe9ea/vaccines-12-00532-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b874/11126006/c8f72f6fe9ea/vaccines-12-00532-g001.jpg

相似文献

1
The Limitations of a Hypothetical All-Variant COVID-19 Vaccine: A Simulation Study.一种假设的全变体新冠疫苗的局限性:一项模拟研究
Vaccines (Basel). 2024 May 13;12(5):532. doi: 10.3390/vaccines12050532.
2
COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination.印度的新冠疫情动态、严重急性呼吸综合征冠状病毒2(SARS-CoV-2)德尔塔变异株及其对疫苗接种的影响
medRxiv. 2021 Nov 22:2021.06.21.21259268. doi: 10.1101/2021.06.21.21259268.
3
Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study.非药物干预措施、疫苗接种和 SARS-CoV-2 德尔塔变异株在英国:一项数学建模研究。
Lancet. 2021 Nov 13;398(10313):1825-1835. doi: 10.1016/S0140-6736(21)02276-5. Epub 2021 Oct 28.
4
Evaluating the Impact of SARS-CoV-2 Variants on the COVID-19 Epidemic and Social Restoration in the United States: A Mathematical Modelling Study.评估 SARS-CoV-2 变异株对美国 COVID-19 疫情和社会恢复的影响:一项数学建模研究。
Front Public Health. 2022 Jan 10;9:801763. doi: 10.3389/fpubh.2021.801763. eCollection 2021.
5
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.新冠病毒-19(Sars-Cov-2)的英国变体不应造成疫苗问题。
J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E.
6
Lifting non-pharmaceutical interventions following the COVID-19 pandemic - the quiet before the storm?解除新冠肺炎大流行后的非药物干预措施——暴风雨前的宁静?
Expert Rev Vaccines. 2022 Nov;21(11):1541-1553. doi: 10.1080/14760584.2022.2117693. Epub 2022 Sep 5.
7
Vaccination as an alternative to non-drug interventions to prevent local resurgence of COVID-19.疫苗接种作为非药物干预措施的替代方案,以预防 COVID-19 在当地的再次爆发。
Infect Dis Poverty. 2022 Mar 26;11(1):36. doi: 10.1186/s40249-022-00960-6.
8
Association of Simulated COVID-19 Vaccination and Nonpharmaceutical Interventions With Infections, Hospitalizations, and Mortality.模拟 COVID-19 疫苗接种和非药物干预措施与感染、住院和死亡的关联。
JAMA Netw Open. 2021 Jun 1;4(6):e2110782. doi: 10.1001/jamanetworkopen.2021.10782.
9
Impact of non-pharmaceutical interventions and vaccination on COVID-19 outbreaks in Nunavut, Canada: a Canadian Immunization Research Network (CIRN) study.加拿大努纳武特地区非药物干预和疫苗接种对 COVID-19 疫情的影响:加拿大免疫研究网络(CIRN)研究。
BMC Public Health. 2022 May 25;22(1):1042. doi: 10.1186/s12889-022-13432-1.
10
Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.两剂蛋白亚单位疫苗 MVC-COV1901 初免后加强接种多剂 mRNA 疫苗可增强针对新型 SARS-CoV-2 变异株的体液和细胞免疫应答。
Microbiol Spectr. 2022 Oct 26;10(5):e0060922. doi: 10.1128/spectrum.00609-22. Epub 2022 Aug 25.

本文引用的文献

1
Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years - VISION and IVY Networks, September 2023-January 2024.2023-2024 年更新版(单价 XBB.1.5)COVID-19 疫苗对免疫功能正常成年人 COVID-19 相关急诊和紧急护理就诊以及住院的临时有效性- VISION 和 IVY 网络,2023 年 9 月至 2024 年 1 月。
MMWR Morb Mortal Wkly Rep. 2024 Feb 29;73(8):180-188. doi: 10.15585/mmwr.mm7308a5.
2
Evaluation of the US COVID-19 Scenario Modeling Hub for informing pandemic response under uncertainty.评估美国 COVID-19 情景建模中心在不确定情况下为大流行应对提供信息的能力。
Nat Commun. 2023 Nov 20;14(1):7260. doi: 10.1038/s41467-023-42680-x.
3
Estimates of SARS-CoV-2 Seroprevalence and Incidence of Primary SARS-CoV-2 Infections Among Blood Donors, by COVID-19 Vaccination Status - United States, April 2021-September 2022.2021 年 4 月至 2022 年 9 月期间,按 COVID-19 疫苗接种状况划分的献血者中 SARS-CoV-2 血清流行率和原发性 SARS-CoV-2 感染发生率估计值-美国。
MMWR Morb Mortal Wkly Rep. 2023 Jun 2;72(22):601-605. doi: 10.15585/mmwr.mm7222a3.
4
Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023.2022 年 9 月至 2023 年 4 月,在有和无免疫功能低下情况的成年人中,二价 mRNA 疫苗预防 COVID-19 相关住院和重症的持久性估计 - VISION 网络。
MMWR Morb Mortal Wkly Rep. 2023 May 26;72(21):579-588. doi: 10.15585/mmwr.mm7221a3.
5
Evaluation of Waning of SARS-CoV-2 Vaccine-Induced Immunity: A Systematic Review and Meta-analysis.评估 SARS-CoV-2 疫苗诱导免疫的衰减:系统评价和荟萃分析。
JAMA Netw Open. 2023 May 1;6(5):e2310650. doi: 10.1001/jamanetworkopen.2023.10650.
6
COVID-19 vaccination: The road ahead.COVID-19 疫苗接种:前路漫漫。
Science. 2022 Mar 11;375(6585):1127-1132. doi: 10.1126/science.abn1755. Epub 2022 Mar 10.
7
The effective reproductive number of the Omicron variant of SARS-CoV-2 is several times relative to Delta.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)奥密克戎变异株的有效繁殖数相对于德尔塔变异株而言是其数倍。
J Travel Med. 2022 May 31;29(3). doi: 10.1093/jtm/taac037.
8
The importance of non-pharmaceutical interventions during the COVID-19 vaccine rollout.在 COVID-19 疫苗推出期间,非药物干预的重要性。
PLoS Comput Biol. 2021 Sep 10;17(9):e1009346. doi: 10.1371/journal.pcbi.1009346. eCollection 2021 Sep.
9
The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus.与原始的 SARS-CoV-2 病毒相比,SARS-CoV-2 的 Delta 变体的繁殖数要高得多。
J Travel Med. 2021 Oct 11;28(7). doi: 10.1093/jtm/taab124.
10
Association of Simulated COVID-19 Vaccination and Nonpharmaceutical Interventions With Infections, Hospitalizations, and Mortality.模拟 COVID-19 疫苗接种和非药物干预措施与感染、住院和死亡的关联。
JAMA Netw Open. 2021 Jun 1;4(6):e2110782. doi: 10.1001/jamanetworkopen.2021.10782.